Evidence map›Paper›PMID 39092569›Full record

ArticleInternational journal of molecular medicine2024

NCAPD2 augments the tumorigenesis and progression of human liver cancer via the PI3K‑Akt‑mTOR signaling pathway.

Jiang-Xue Gu, Ke Huang, Wei-Lin Zhao, Xiao-Ming Zheng, Yu-Qin Wu, Shi-Rong Yan, Yu-Gang Huang, Pei Hu

Abstract read
In one paragraph

Article in International journal of molecular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Regulation Ratio: A Singular Multi-Omic Measurement of Gene Regulatory Mechanisms.Computational and structural biotechnology journal · 2026
    Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jiang-Xue Gu *Department of Laboratory Medicine and Department of Pathology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
Ke Huang *Department of Laboratory Medicine and Department of Pathology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
Wei-Lin Zhao *Department of Laboratory Medicine and Department of Pathology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
Xiao-Ming ZhengCentral Operating Room, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
Yu-Qin WuCentral Operating Room, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
Shi-Rong YanHubei Key Laboratory of Embryonic Stem Cell Research, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
Yu-Gang HuangDepartment of Laboratory Medicine and Department of Pathology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
Pei HuDepartment of Laboratory Medicine and Department of Pathology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non‑SMC condensin I complex subunit D2 (

Indexed as

Cell ProliferationLiver NeoplasmsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionTOR Serine-Threonine KinasesApoptosisCarcinogenesisCell Cycle ProteinsCell Line, TumorCell MovementDisease ProgressionEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansCell Cycle ProteinsMTOR protein, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTOR Serine-Threonine Kinasesc‑Mycepithelial‑mesenchymal transitionliver cancernon‑SMC condensin I complex subunit D2phosphatidylinositol 3‑kinase‑Akt‑mammalian target of rapamycintumor survival and progression

Identifiers

PMID39092569
PMCPMC11315656

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.